NewAmsterdam Pharma NAMS
NASDAQ NAMS
$25.40 -0.45 (-1.74%)
At close: Sep 4, 2026 · 4:00 PM EDT

NewAmsterdam Pharma (NAMS) Selling, General & Administrative (2023 - 2026)

Analysis

NewAmsterdam Pharma (NAMS) Selling, General & Administrative (2023 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) SG&A (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 582.20 Mn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 662.10 Mn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -417.00 Mn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 216.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - 110.21 Mn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 593.21 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 347.92 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - 161.89 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 247.47 Mn
10 NewAmsterdam Pharma 3.13 Bn 3.13 Bn - 26.89 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 26.89 Mn
Mar 31, 2026 23.45 Mn
Dec 31, 2025 27.42 Mn
Sep 30, 2025 24.52 Mn
Jun 30, 2025 27.26 Mn
Mar 31, 2025 27.15 Mn
Dec 31, 2024 21.11 Mn
Sep 30, 2024 18.41 Mn
Jun 30, 2024 16.48 Mn
Mar 31, 2024 14.45 Mn
Dec 31, 2023 10.59 Mn
Sep 30, 2023 9.13 Mn
Jun 30, 2023 9.86 Mn
Mar 31, 2023 8.06 Mn